ANGLE is a world leading liquid biopsy company with pioneering products in cancer diagnostics and foetal health. ANGLEs lead product is the Parsortix cell separation system, which can capture very rare cells from blood. This includes circulating tumour cells CTCs in cancer patient blood even when there is less than one CTC in one billion healthy cells. The resulting liquid biopsy simple blood test enables the investigation of mutations in the patient s cancer for personalised cancer care. ANGLE has launched a product for the research market and has secured CE Mark regulatory approval for the clinical market in Europe. The FDA authorization is in process. ANGLE is also undertaking clinical studies, the first on of which is in Ovarian Cancer for a clinical application to triage women having surgery for an abnormal pelvic mass to identify those with ovarian cancer. patient clinical studies in both Europe and the US have reported positive headline data and the test is being optimized before moving to validation studies. ANGLE has announced the acquisition of certain assets of Axela Inc, a novel multiplex diagnostic tool for the analysis of DNA, RNA and proteins.
Quote | Angle Plc Surrey ADR (OTCMKTS:ANPCY)
Last: | $2.44 |
---|---|
Change Percent: | 9.02% |
Open: | $2.22 |
Close: | $2.44 |
High: | $2.44 |
Low: | $2.22 |
Volume: | 662 |
Last Trade Date Time: | 07/15/2024 03:00:00 am |
News | Angle Plc Surrey ADR (OTCMKTS:ANPCY)
GUILDFORD, SURREY / ACCESSWIRE / July 11, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed. For further information: Notes for editors About ANG...
GUILDFORD, SURREY / ACCESSWIRE / June 18, 2024 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report a...
Message Board Posts | Angle Plc Surrey ADR (OTCMKTS:ANPCY)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Angle Plc Surrey ADR Company Name:
ANPCY Stock Symbol:
OTCMKTS Market:
Angle Plc Surrey ADR Website:
GUILDFORD, SURREY / ACCESSWIRE / July 11, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed. For further information: Notes for editors About ANG...
GUILDFORD, SURREY / ACCESSWIRE / June 18, 2024 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report a...
PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT THE 2024 ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH ANGLE presenting two posters highlighting the utility of CTC & ctDNA dual analysis and ANGLE's DNA Damage Response assay GUILDFORD, SURREY / ACCESSWIRE / June 11, ...